Next Article in Journal
Acknowledgement to Reviewers of Laws in 2016
Next Article in Special Issue
Collegiality, Therapy and Mediation—The Contribution of Experts in Swedish Mental Health Law
Previous Article in Journal
What Has Limited the Impact of UK Disability Equality Law on Social Justice?
Previous Article in Special Issue
Access to Preventive Health Care for Undocumented Migrants: A Comparative Study of Germany, The Netherlands and Spain from a Human Rights Perspective
Article Menu

Export Article

Open AccessFeature PaperArticle

Assessing the UN High-Level Panel on Access to Medicines Report in Light of the Right to Health

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
School of Health Studies, The University of Western Ontario, 1151 Richmond St., London, ON N6A 3K7, Canada
Author to whom correspondence should be addressed.
Academic Editor: Rhonda Powell
Received: 7 July 2016 / Revised: 24 October 2016 / Accepted: 26 October 2016 / Published: 22 November 2016
(This article belongs to the Special Issue The Intersection of Human Rights Law and Health Law)
Full-Text   |   PDF [200 KB, uploaded 22 November 2016]


Access to medicines is the lynchpin to realizing a range of human rights, public health and development imperatives. However, without strong policy action to increase access to affordable medicines, there is little hope of achieving the Sustainable Development Goals or of realizing the human right to health. Access to medicines is a fundamental element of the right to health, and the majority of states are bound by core obligations in this regard. Accordingly, states must ensure that this critical human rights, public health and development interest is appropriately prioritized against inadequate resource allocations and competing private or trade interests. This is an imperative which we have argued should have framed the deliberations of the UN High Level Panel on Access to Medicines, convened to propose solutions to the “policy incoherence” between international human rights, trade rules and public health that is impeding access to medicines and the right to health for millions. In this article we explore interpretations in international human rights law regarding state duties towards medicines that should have guided these deliberations, and which were presented by the first author in a submission to the panel. We argue that at least two clear right to health duties support the High Level Panel’s recommendations: (1) the duty to prevent unreasonably high costs for medicines from denying large segments of the population their rights to health; and (2) the core obligation to provide essential medicines. Consequently, we explore three areas of action implied by these duties: (1) consistent implementation of human rights impact assessment; (2) institutionalizing the Agreement on Trade-Related Intellectual Property Rights (TRIPS) flexibilities in law and policy; (3) making permanent the waiver of TRIPS for least developed countries (LDC), and waiving the application of TRIPS to essential medicines in low and middle-income countries. Finally, we assess the extent to which the recommendations made by the Panel’s final report comply with these duties and accordingly with the right to health. View Full-Text
Keywords: human rights law; access to medicine; high-level panel; UN human rights law; access to medicine; high-level panel; UN
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Forman, L.; Abdillahi, I.; Samuel, J. Assessing the UN High-Level Panel on Access to Medicines Report in Light of the Right to Health. Laws 2016, 5, 43.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Laws EISSN 2075-471X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top